Cardiff Oncology, Inc. (CRDF) Tops Q3 EPS by 2c

Cardiff Oncology, Inc. (NASDAQ: CRDF) reported Q3 EPS of ($0.25), $0.02 better than the analyst estimate of ($0.27). Revenue for the quarter came in at $165 thousand versus the consensus estimate of $80 thousand.

For earnings history and earnings-related data on Cardiff Oncology, Inc. (CRDF) click here.

You May Also Be Interested In

• Venu Holding (VENU) PT Lowered to $8.70 at Freedom Broker
• Stifel Downgrades Weave Communications Inc (WEAV) to Hold
• Deere & Co. (DE) call put ratio 1.1 calls to 1 put into quarter results